- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04743245
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
A Post Approval Study to Evaluate the Delivery of Hyperoxemic Super Saturated Oxygen Therapy for 60 Minutes in Anterior AMI Patients Compared to PCI
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Shailaja Lakma
- Phone Number: 9253367743
- Email: slakma@zoll.com
Study Contact Backup
- Name: Jeffrey Creech, PhD
- Phone Number: 3233096949
- Email: jcreech@zoll.com
Study Locations
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01199
- Recruiting
- Baystate Medical Center
-
Principal Investigator:
- Amir Lotfi, MD
-
Contact:
- Christine Callahan, RN
- Email: Christine.Callahan@baystatehealth.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-
Pre-PCI:
- The subject must be ≥18 years of age.
- AMI must be anterior (ST-segment elevation >1 mm in two or more contiguous leads between V1 and V4 or new left bundle branch block).
- The subject or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written informed consent, approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).
Subject and his/her physician agree to all required follow-up procedures and visits.
ANGIOGRAPHIC INCLUSION CRITERIA: These are evaluated after the subject has provided signed Informed Consent and has undergone cardiac catheterization and PCI if indicated:
- Based on coronary anatomy, PCI is indicated for revascularization of the culprit lesion(s) with use of a commercially available coronary stent (bare metal or drug-eluting, at operator discretion) in the LAD.
- The primary stented infarct-related lesion(s) must be in the proximal and/or mid-LAD coronary artery (other lesions in the LAD target vessel, including diagonal branches, may be treated if clinically indicated).
- Successful angioplasty is completed <6 hrs from symptom onset, as documented by 30% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no major complications such as perforation or shock.
- Expected ability to place the SSO2 delivery catheter in the coronary ostium of the left main coronary system to deliver SSO2 Therapy with stable, coaxial alignment.
- Systemic arterial pO2 greater than or equal to 80 mmHg as measured by arterial blood gas (may be repeated if low after supplemental O2 administration).
Exclusion Criteria:
-
Patients will be excluded if ANY of the following conditions apply:
GENERAL EXCLUSION CRITERIA
Pre-PCI:
- Prior CABG surgery.
- Prior myocardial infarction or known prior systolic dysfunction (e.g. due to cardiomyopathy); this criterion does not include left ventricular dysfunction induced by the acute MI.
- An elective surgical procedure is planned during the first 30 days post-enrollment.
- Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the anterior AMI.
- Subjects who have previously undergone an angioplasty or stenting procedure in the left anterior descending coronary artery.
Contraindication to MRI imaging, including any of the following:
- Non-MRI compatible cardiac pacemaker or implantable defibrillator;
- Non-MRI compatible aneurysm clip or other metallic implants;
- Neural Stimulator (i.e., TENS unit);
- Any implanted or magnetically activated device (insulin pump);
- Any type of non-MRI compatible ear implant;
- Metal shavings in the orbits;
- Any indwelling metallic foreign body, shrapnel, or bullet;
- Any condition contraindicating MRI, including claustrophobia;
- Inability to follow breath hold instructions or to maintain a breath hold for >15 seconds; and
- Known hypersensitivity or contraindication to gadolinium contrast.
- Known impaired renal function (creatinine clearance <30 ml/min/1.73 m2 by the MDRD formula) or on dialysis.
- Known platelet count <100,000 cells/mm3 or >700,000 cells/mm3 or a known Hgb <10 g/dL.
- Subject has active bleeding or a history of bleeding diathesis or coagulopathy (including heparin induced thrombocytopenia), or refusal to receive blood transfusions if necessary.
- History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke.
- Stroke or transient ischemic attack within the past six (6) months, or any permanent neurological defect.
- Gastrointestinal or genitourinary bleeding within the last two (2) months, or any major surgery (including CABG) within six weeks of enrollment.
- Subject has received any organ transplant or is on a waiting list for any organ transplant.
- Subject has other medical illness (e.g., cancer, dementia) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with the protocol, confound the data interpretation, or is associated with life expectancy of less than one year.
- Subject has a known hypersensitivity or contraindication to any of the required study medications or contrast that cannot be adequately premedicated.
- Subjects presenting with or developing in the cath lab prior to completion of the PCI procedure any of the following conditions: cardiogenic shock (SBP <80 mmHg for >30 minutes), or requiring IV pressors or emergent placement of an intra-aortic balloon pump (IABP), Impella, or other hemodynamic support for hypotension treatment, or cardiopulmonary resuscitation for >10 minutes, or ventricular fibrillation or tachycardia requiring cardioversion or defibrillation.
- Severe known cardiac valvular stenosis or insufficiency, pericardial disease, or cardiomyopathy.
- Subject is a member of a vulnerable population or has any significant medical or social condition which in the investigator's opinion may interfere with the subject's participation in the study or ability to comply with follow-up procedures, including MRI (e.g. alcoholism, dementia, lives far from the research center, etc.).
- Current participation in other investigational device or drug study that has not reached its primary endpoint.
- Previous enrollment in this study.
- Subject is currently hospitalized for definite or suspected COVID-19.
- Subject has previously been symptomatic with or hospitalized for COVID-19 unless he/she has been discharged (if hospitalized) and asymptomatic for ≥8 weeks and had returned to his/her prior baseline (pre-COVID) clinical condition.
Subject is asymptomatic (never ill) and COVID-19 PCR/antigen or antibody test is positive within the prior 4 weeks unless subject remained asymptomatic for≥4 weeks after the last positive test.
ANGIOGRAPHIC EXCLUSION CRITERIA: These are evaluated after the subject has provided signed Informed Consent and has undergone cardiac catheterization and PCI if indicated:
- Treatment during the index procedure of any lesion in either the left main, LCX (including the ramus), and/or RCA.
- Post-index procedure planned intervention within 7 days (i.e., PCI of non-target lesions in any vessel, or CABG). Note: Planned revascularization (PCI or bypass) of a non-target lesion >7 days following the index procedure and after performance of the 2-7day MRI is allowed.
- Anterior MI is due to thrombosis within or adjacent to a previously implanted stent.
- Left ventriculography (mandatory before or after PCI, but in all cases before randomization) demonstrates severe mitral regurgitation, a ventricular septal defect, a pseudoaneurysm, aortic dissection or other mechanical complications of MI.
- Any left main coronary artery stenosis >20%.
- Any untreated LAD or diagonal branch lesion is present with diameter stenosis > 50% in a vessel with reference vessel diameter > 2.0 mm (visually estimated).
- Presence of a non-stented coronary dissection with NHLBI grade >B upon completion of the PCI procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PCI with SSO2 therapy
AMI subjects treated with SSO2 Therapy following PCI with stenting
|
SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)
Standard Care of PCI
|
Active Comparator: anterior AMI patients treated with PCI and stenting within 6 hours
Control group receiving PCI with stenting alone
|
Standard Care of PCI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1-year rate of Net Adverse Clinical Events (NACE)
Time Frame: 12 months
|
The composite NACE endpoint includes a hierarchical total of the following events:
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in infarct size between SSO2 Therapy and standard therapy in patients
Time Frame: At 2-7 days and at 6 month
|
Change from 2-7 days to 6 months in MRI endpoints
|
At 2-7 days and at 6 month
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Gregg Stone, MD, Mount Sinai Hospital
- Principal Investigator: James Blankenship, MD, University of New Mexico
- Study Director: Amir S Lotfi, MD, Baystate Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMIHOT III 09 November 2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myocardial Infarction
-
Henry Ford Health SystemAbiomed Inc.Enrolling by invitationAcute Myocardial Infarction | Cardiogenic Shock | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction | NSTEMI | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction of Right Ventricle (Disorder) | Acute Myocardial Infarction of Left VentricleUnited States
-
Jordan Collaborating Cardiology GroupCardiovascular Academy GroupTerminatedTriggers of Acute Myocardial Infarction | Time of Onset of Acute Myocardial Infarction | Long-term Prognosis After Acute Myocardial InfarctionJordan
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
Medical Center of South ArkansasWithdrawnAcute Coronary Syndrome | Acute ST Segment Elevation Myocardial InfarctionUnited States
-
Yuan's General HospitalKaohsiung Veterans General Hospital.; Sin-Lau HospitalUnknownAcute Myocardial Infarction, of Inferolateral Wall | Acute Myocardial Infarction, of Inferoposterior WallTaiwan
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Acute Coronary Syndrome | Acute Myocardial Infarction | Metabolic DisturbanceGreece
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Sheba Medical CenterCompletedNon ST Elevation Myocardial Infarction | Acute Coronary SyndromesIsrael
-
Medstar Health Research InstituteWithdrawnST-elevation Myocardial Infarction | Acute Myocardial InfarctionUnited States
-
Hennepin Healthcare Research InstituteSiemens HealthineersActive, not recruitingAcute Coronary Syndrome | Acute Myocardial InfarctionUnited States
Clinical Trials on TherOx DownStream System
-
TherOxCompletedAnterior Wall Acute Myocardial InfarctionUnited States
-
TherOxRecruitingAnterior Acute Myocardial Infarction (AMI)United States
-
TherOxWithdrawn
-
University of PadovaAzienda Ospedaliera di PadovaUnknownUnstable Angina or Non ST Elevated Myocardial InfarctionItaly
-
ResMedCompleted
-
Federal University of São PauloCompletedAdverse Reaction to Systemic AgentsBrazil
-
KineticureCompletedOsteoarthritis | Knee PainUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Molnlycke Health Care ABCompletedEvaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.Diabetes | Foot UlcersUnited Kingdom